Negative effect of cannabinoids on the course of paranoid schizophrenia
https://doi.org/10.31549/2542-1174-2019-2-79-84
Abstract
Over the period of 2013–2018 113 patients with approved diagnosis of paranoid schizophrenia (suffering for more than fi ve years) associated with the cannabinoid use dependency syndrome who had taken up the cannabinoid use before the paranoid schizophrenia manifestation (mean age in the group was 32 ± 4) were chosen for the investigation during which the effect of cannabinoids on the course of paranoid schizophrenia was studied. The control group consisted of 113 patients with paranoid schizophrenia who did not use psychoactive drugs including cannabinoids (mean age in the group was 34 ± 2). It was revealed that the early cannabinoid use is the factor that signifi cantly increases the risk of paranoid schizophrenia development and aggravates its course that is proved by the earlier manifestation of the disease (at the age of 16 ± 4 in the main group versus 22 ± 3 in the control group), a rapid change of syndromes with the forming of negative symptomatology and the signifi cant decrease of a social activity level (the time of hospital stay was less than a year in the main group — 82 % of cases, in the control group — 13 % of cases).
About the Authors
I. Yu. Klimova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Klimova Irina Yuryevna — Teaching Assistant of the Department of Psychiatry, Narcology, Psychotherapy and Clinical Psychology
52, Krasny Prospect, Novosibirsk, 630091
A. A. Ovchinnikov
Novosibirsk State Medical University
Russian Federation
Russian Federation
Ovchinnikov Anatoliy Aleksandrovich — Dr. Sci. (Med.), Professor, Head of the Department of Psychiatry, Narcology, Psychotherapy and Clinical Psychology
Novosibirsk
References
1. Bohan N.A., Selivanov G.Y., Blonskiy K.A., Lavrova U.A. (2018). Features of socio-psychologic adaptation of the patients with paranoid form of schizophrenia complicated with synthetic cannabinoids (spice) dependancy. Siberian Herald of Psychiatry and Addiction Psychiatry, 2, 99, 93–98.
2. Ivanova S.A., Osmanova D.Z., Boiko A.S. et al. (2018). Antipsychotic-induced hyperprolactinemia: pharmacogenetic aspects. Siberian Herald of Psychiatry and Addiction Psychiatry, 2, 99, 21–27.
3. Klimova I.Yu., Ovchinnikov A.A. (2015). Pathomorphism of cannabinoid abuse at patients suffering from schizophrenia. Medicine and Education in Siberia, 3, 37.
4. Klimova I.Yu., Ovchinnikov A.A. (2015). Features of remission at schizophrenia of comorbid cannabinoid abuse. Medicine and Education in Siberia, 6, 29.
5. Nevidimova T.I., Savochkina D.N., Masterova E.I., Bokhan N.A. (2018). Results and perspectives of research of between sensory and immune system in addictive disorders. Siberian Herald of Psychiatry and Addiction Psychiatry, 2, 99, 56–63.
6. Tandon R., Gaebel W., Barch D. M. et al. (2013). Defi nition and description of schizophrenia in the DSM-5. Schizophr. Res., 150, 3–10.
7. Iseger T.A., Bossong M.G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr. Res., 162, 153–161.
8. Radhakrishnan R., Wilkinson S.T., D’Souza D.C. (2014). Gone to pot — a review of the association between cannabis and psychosis. Front. Psychiatry, 5, 54.
9. Goncharova A.A., Kornetova E.G., Dubrovskaya V.V., Sorokina V.A., Semke A. V. (2018). Clinical dynamic and clinico-social factors in akathisia in patients with schizophrenia, receiving antipsychotic therapy. Siberian Herald of Psychiatry and Addiction Psychiatry, 3, 100, 46–52.
Review
For citations:
Klimova I.Yu., Ovchinnikov A.A. Negative effect of cannabinoids on the course of paranoid schizophrenia. Journal of Siberian Medical Sciences. 2019;(2):79-84. https://doi.org/10.31549/2542-1174-2019-2-79-84
Views:
258
Email this article 